Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.

Amoils M, Kim J, Lee C, Sunwoo JB, Colevas AD, Aasi SZ, Hollmig ST, Ma Y, Divi AV.

Otolaryngol Head Neck Surg. 2018 Jul 1:194599818788057. doi: 10.1177/0194599818788057. [Epub ahead of print]

PMID:
30012051
2.

Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.

Gao RW, Teraphongphom NT, van den Berg NS, Martin BA, Oberhelman NJ, Divi V, Kaplan MJ, Hong SS, Lu G, Ertsey R, Tummers WS, Gomez AJ, Holsinger FC, Kong CS, Colevas AD, Warram JM, Rosenthal EL.

Cancer Res. 2018 Jul 2. pii: canres.0878.2018. doi: 10.1158/0008-5472.CAN-18-0878. [Epub ahead of print]

PMID:
29967260
3.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

PMID:
29884413
4.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Jun 4. pii: theoncologist.2017-0674. doi: 10.1634/theoncologist.2017-0674. [Epub ahead of print]

PMID:
29866947
5.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
6.

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.

Gao RW, Teraphongphom N, de Boer E, van den Berg NS, Divi V, Kaplan MJ, Oberhelman NJ, Hong SS, Capes E, Colevas AD, Warram JM, Rosenthal EL.

Theranostics. 2018 Mar 28;8(9):2488-2495. doi: 10.7150/thno.24487. eCollection 2018.

7.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA.

J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.

8.

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.

Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, Boothroyd D, Colevas AD.

Oncologist. 2018 Jul;23(7):764-e86. doi: 10.1634/theoncologist.2017-0618. Epub 2018 Mar 14.

10.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

PMID:
28651929
11.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
12.

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME.

JAMA Dermatol. 2017 Jul 1;153(7):694-697. doi: 10.1001/jamadermatol.2017.0989.

13.

Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.

Amoils M, Lee CS, Sunwoo J, Aasi SZ, Hara W, Kim J, Sirjani D, Colevas AD, Chang AL, Divi V.

Head Neck. 2017 May;39(5):881-885. doi: 10.1002/hed.24692. Epub 2017 Mar 2.

PMID:
28252823
14.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

15.

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.

Makkouk A, Sundaram V, Chester C, Chang S, Colevas AD, Sunwoo JB, Maecker H, Desai M, Kohrt HE.

Ann Oncol. 2017 Feb 1;28(2):415-420. doi: 10.1093/annonc/mdw570.

PMID:
27831501
16.

Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.

Tran DC, Colevas AD, Chang AL.

JAMA Dermatol. 2017 Jan 1;153(1):92-94. doi: 10.1001/jamadermatol.2016.3884. No abstract available.

PMID:
27784038
17.

Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, Lin SJ, Guo QJ, Sze HC, Chen YB, Xiao YP, Kan WK, O'Sullivan B, Xu W, Le QT, Glastonbury CM, Colevas AD, Weber RS, Lydiatt W, Shah JP, Lee AW.

Cancer. 2016 Nov 15;122(21):3307-3315. doi: 10.1002/cncr.30198. Epub 2016 Jul 19.

18.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.

N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.

19.

BRAF inhibitor therapy of primary ameloblastoma.

Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):518-9. doi: 10.1016/j.oooo.2016.05.017. Epub 2016 Jul 5. No abstract available.

PMID:
27651290
20.

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI.

Invest New Drugs. 2016 Oct;34(5):604-13. doi: 10.1007/s10637-016-0374-3. Epub 2016 Jul 16.

PMID:
27424159
21.

Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy.

Beswick DM, Holsinger FC, Kaplan MJ, Fischbein NJ, Hara W, Colevas AD, Le QT, Berry GJ, Hwang PH.

Laryngoscope. 2016 Sep;126(9):1977-80. doi: 10.1002/lary.25996. Epub 2016 Jun 10.

PMID:
27283472
22.

BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.

Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jul;122(1):e5-7. doi: 10.1016/j.oooo.2015.12.016. Epub 2016 Feb 23.

PMID:
27209484
23.

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Narayanan S, Colevas AD.

Curr Treat Options Oncol. 2016 Jun;17(6):30. doi: 10.1007/s11864-016-0404-6. Review.

PMID:
27139457
24.

Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas.

Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V.

Cancer. 2016 May 1;122(9):1388-97. doi: 10.1002/cncr.29932. Epub 2016 Mar 11.

25.

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

Iberri DJ, Colevas AD.

Oncologist. 2016 Mar;21(3):391. doi: 10.1634/theoncologist.2015-0177erratum. No abstract available.

26.

Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.

Ally MS, Ransohoff K, Sarin K, Atwood SX, Rezaee M, Bailey-Healy I, Kim J, Beachy PA, Chang AL, Oro A, Tang JY, Colevas AD.

JAMA Dermatol. 2016 Apr;152(4):452-6. doi: 10.1001/jamadermatol.2015.5473.

27.

Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.

Zhu GA, Lira R, Colevas AD.

Oral Oncol. 2016 Feb;53:36-41. doi: 10.1016/j.oraloncology.2015.11.018. Epub 2015 Dec 9.

PMID:
26684543
28.

Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

Pan JJ, Ng WT, Zong JF, Chan LL, O'Sullivan B, Lin SJ, Sze HC, Chen YB, Choi HC, Guo QJ, Kan WK, Xiao YP, Wei X, Le QT, Glastonbury CM, Colevas AD, Weber RS, Shah JP, Lee AW.

Cancer. 2016 Feb 15;122(4):546-58. doi: 10.1002/cncr.29795. Epub 2015 Nov 20.

29.

New Diseases and New Treatments--Head and Neck Cancer Updates.

Colevas AD.

Hematol Oncol Clin North Am. 2015 Dec;29(6):xiii-xiv. doi: 10.1016/j.hoc.2015.08.004. Epub 2015 Sep 15. No abstract available.

PMID:
26568555
30.

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM.

J Natl Compr Canc Netw. 2015 Nov;13(11):1337-46.

PMID:
26553764
31.

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

Iberri DJ, Colevas AD.

Oncologist. 2015 Dec;20(12):1393-403. doi: 10.1634/theoncologist.2015-0177. Epub 2015 Oct 7. Review. Erratum in: Oncologist. 2016 Mar;21(3):391.

32.

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.

Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD.

JAMA Dermatol. 2016 Jan;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705. No abstract available.

PMID:
26422398
33.

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM.

Cancer Chemother Pharmacol. 2015 Nov;76(5):897-907. doi: 10.1007/s00280-015-2868-7. Epub 2015 Sep 11.

34.

Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Colevas AD.

J Natl Compr Canc Netw. 2015 May;13(5):e37-48. Review.

PMID:
26158134
35.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

36.

Ameloblastoma: a clinical review and trends in management.

McClary AC, West RB, McClary AC, Pollack JR, Fischbein NJ, Holsinger CF, Sunwoo J, Colevas AD, Sirjani D.

Eur Arch Otorhinolaryngol. 2016 Jul;273(7):1649-61. doi: 10.1007/s00405-015-3631-8. Epub 2015 Apr 30. Review.

PMID:
25926124
37.

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.

Pollom EL, Bui TT, Chang AL, Colevas AD, Hara WY.

JAMA Dermatol. 2015 Sep;151(9):998-1001. doi: 10.1001/jamadermatol.2015.0326.

PMID:
25874733
38.

Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.

Gruber JJ, Colevas AD.

Oncologist. 2015 Feb;20(2):113-26. doi: 10.1634/theoncologist.2014-0313. Epub 2015 Jan 23. Review.

39.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A.

Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.

40.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

41.

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S.

Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23.

42.

CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma.

Murillo-Sauca O, Chung MK, Shin JH, Karamboulas C, Kwok S, Jung YH, Oakley R, Tysome JR, Farnebo LO, Kaplan MJ, Sirjani D, Divi V, Holsinger FC, Tomeh C, Nichols A, Le QT, Colevas AD, Kong CS, Uppaluri R, Lewis JS Jr, Ailles LE, Sunwoo JB.

Oncotarget. 2014 Aug 30;5(16):6854-66.

43.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2014 Jun;124(6):2668-82. doi: 10.1172/JCI73014. Epub 2014 May 16.

44.

Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.

Colevas AD, Lira RR, Colevas EA, Lavori PW, Chan C, Shultz DB, Chang KW.

Head Neck. 2015 Aug;37(8):1102-7. doi: 10.1002/hed.23714. Epub 2014 Jul 11.

45.

Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.

Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, Pinto H, Lee-Enriquez N, Kong C, Le QT.

Head Neck. 2015 Mar;37(3):386-92. doi: 10.1002/hed.23609. Epub 2014 Apr 16.

PMID:
24431011
46.
47.

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):917-23. Erratum in: J Natl Compr Canc Netw. 2013 Dec 1;11(12):1458.

PMID:
23946171
48.

Biased view of the role of site-specific therapy in carcinoma of unknown primary.

Percival ME, Colevas AD.

J Clin Oncol. 2013 Jul 1;31(19):2512-3. doi: 10.1200/JCO.2013.49.5036. Epub 2013 Jun 3. No abstract available.

PMID:
23733770
49.

Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity.

Colevas AD.

Head Neck. 2014 Jan;36(1):34-42. doi: 10.1002/hed.23253. Epub 2013 Apr 30.

PMID:
23633438
50.

Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas.

Zeidan YH, Shultz DB, Murphy JD, An Y, Chan C, Kaplan MJ, Colevas AD, Kong C, Chang DT, Le QT.

Laryngoscope. 2013 Nov;123(11):2675-80. doi: 10.1002/lary.24081. Epub 2013 Apr 1.

PMID:
23553253

Supplemental Content

Loading ...
Support Center